Genflow Biosciences said that its second European patent application, titled “SIRT6 Variant for NASH” (Application No. 23821586.7; Publication No. EP4630038), has been published in the European Patent Bulletin.
The company said that the publication follows its entry into the European phase under the Patent Cooperation Treaty and grants provisional protection under Article 67(3) of the European Patent Convention, enabling Genflow to claim retroactive damages for infringing acts occurring after the publication date once the patent is formally granted and national validations are completed.
Genflow claims this development strengthens its intellectual-property framework for its SIRT6 gene-variant technologies, expanding therapeutic reach into metabolic and age-related disorders including non-alcoholic steatohepatitis (NASH). The new filing complements its earlier European application (EP4338267) covering the core SIRT6 variant for healthy ageing.
The company said that establishing a strong European patent base is key to its upcoming clinical programmes and licensing discussions across its longevity and metabolic-disease platform.
